Products
Lacutamab Biosimilar Monoclonal Antibody (KIR3DL2) for Research
Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lacutamab is a humanised version of anti KIR3DL2 monoclonal antibody clone #1, and has been shown to have potent activity against KIR3DL2-positive tumours.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-290-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody |
| INN Name | Lacutamab |
| Target | CD158k |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | University of Genoa;Innate Pharma |
| Conditions Approved | na |
| Conditions Active | Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome |
| Conditions Discontinued | na |
| Development Tech | na |
About target - KIR3DL2
1. Protein Killer cell immunoglobulin-like receptor 3DL2
2. Gene KIR3DL2
3. Organism Homo sapiens (Human)
Function
Receptor on natural killer (NK) cells and T cells for MHC class I molecules (PubMed:24018270, PubMed:28636952).
Upon binding of peptide-free HLA-F open conformer, negatively regulates NK and T cell effector functions (PubMed:24018270).
Acts as a receptor on astrocytes for HLA-F. Through interaction with HLA-F, may protect motor neurons from astrocyte-induced toxicity (PubMed:26928464).
